Lipid nanoparticle-encapsulated cannabidiol enhances selective cytotoxicity in melanoma cells

Background: Melanoma is the most lethal form of skin cancer, accounting for approximately 325,000 new cases and 57,000 deaths worldwide in 2020 [1], with incidence projected to exceed 500,000 cases annually by 2040 [2]. Despite therapeutic advances, treatment remains limited by drug resistance and off-target toxicity. Cannabidiol (CBD) has shown promising anticancer potential [3,4]; however, its clinical use is hindered by poor physicochemical properties. Lipid nanoparticle-based delivery systems may overcome these limitations by enhancing CBD stability, cellular uptake, and tumor selectivity [5]. Objective: This study aims to evaluate the effect of CBD-loaded lipid nanoparticles (NP-CBD) on cell viability in metastatic melanoma (MeWo) and normal keratinocyte (HaCaT) cell lines, focusing on their ability to enhance cytotoxic efficacy and selectivity compared to free CBD. Methods: MeWo and HaCaT cells were exposed to increasing concentrations (0.05–100 μM) of free CBD or NP-CBD (mean diameter of 205.6 ± 3.4 nm) for 48 h. Cell viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay. Results: Free CBD induced a concentration-dependent reduction in cell viability in both MeWo and HaCaT cells, with comparable IC₅₀ values (4.6 µM and 3.9 µM, respectively), indicating limited selectivity toward tumor cells. In contrast, NP-CBD enhanced cytotoxic effects in MeWo cells (IC₅₀ 3.2 vs 4.6 µM, p = 0.0001), while significantly reducing toxicity in HaCaT keratinocytes (IC₅₀ 8.6 vs 3.9 µM, p < 0.0001). This resulted in a clear shift toward increased tumor cell sensitivity and a more favorable safety profile. Conclusions: Lipid nanoparticle encapsulation significantly improves the biological performance of CBD by enhancing its antitumor activity and selectivity. NP-CBD represents a promising nanotechnology-based strategy to optimize CBD delivery, supporting the development of more effective and less toxic therapeutic approaches for melanoma.

Authors

Publication Details

Journal
Science Letters
Published
2026-04-16
DOI
https://doi.org/10.48797/sl.2026.470
Primary Topic
Cannabis and Cannabinoid Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Lipid nanoparticle-encapsulated cannabidiol enhances selective cytotoxicity in melanoma cells

Marlene Lúcio, Carolina Mota, José Catita, Natanael Videira et al.
Science Letters
Cannabis and Cannabinoid Research
article

Lipid nanoparticle-encapsulated cannabidiol enhances selective cytotoxicity in melanoma cells

Marlene Lúcio, Carolina Mota, José Catita, Natanael Videira, Márcia Carvalho, Carla M. Lopes, Ana Rafaela Sales de Araújo
article en

Abstract

Background: Melanoma is the most lethal form of skin cancer, accounting for approximately 325,000 new cases and 57,000 deaths worldwide in 2020 [1], with incidence projected to exceed 500,000 cases annually by 2040 [2]. Despite therapeutic advances, treatment remains limited by drug resistance and off-target toxicity. Cannabidiol (CBD) has shown promising anticancer potential [3,4]; however, its clinical use is hindered by poor physicochemical properties. Lipid nanoparticle-based delivery systems may overcome these limitations by enhancing CBD stability, cellular uptake, and tumor selectivity [5]. Objective: This study aims to evaluate the effect of CBD-loaded lipid nanoparticles (NP-CBD) on cell viability in metastatic melanoma (MeWo) and normal keratinocyte (HaCaT) cell lines, focusing on their ability to enhance cytotoxic efficacy and selectivity compared to free CBD. Methods: MeWo and HaCaT cells were exposed to increasing concentrations (0.05–100 μM) of free CBD or NP-CBD (mean diameter of 205.6 ± 3.4 nm) for 48 h. Cell viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay. Results: Free CBD induced a concentration-dependent reduction in cell viability in both MeWo and HaCaT cells, with comparable IC₅₀ values (4.6 µM and 3.9 µM, respectively), indicating limited selectivity toward tumor cells. In contrast, NP-CBD enhanced cytotoxic effects in MeWo cells (IC₅₀ 3.2 vs 4.6 µM, p = 0.0001), while significantly reducing toxicity in HaCaT keratinocytes (IC₅₀ 8.6 vs 3.9 µM, p < 0.0001). This resulted in a clear shift toward increased tumor cell sensitivity and a more favorable safety profile. Conclusions: Lipid nanoparticle encapsulation significantly improves the biological performance of CBD by enhancing its antitumor activity and selectivity. NP-CBD represents a promising nanotechnology-based strategy to optimize CBD delivery, supporting the development of more effective and less toxic therapeutic approaches for melanoma.

Science Letters
Good health and well-being
Openalex Percentile: Top 8%
Cannabis and Cannabinoid Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Lipid nanoparticle-encapsulated cannabidiol enhances selective cytotoxicity in melanoma cells — Marlene Lúcio, Carolina Mota, et al. · Science Letters (2026) | TGRS Research Map | TGRS